National Pension Service Grows Position in Humana Inc. (NYSE:HUM)

National Pension Service raised its position in Humana Inc. (NYSE:HUM - Free Report) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 291,916 shares of the insurance provider's stock after purchasing an additional 8,546 shares during the quarter. National Pension Service owned 0.24% of Humana worth $133,642,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC increased its stake in Humana by 2.6% in the third quarter. Dorsey & Whitney Trust CO LLC now owns 817 shares of the insurance provider's stock worth $397,000 after purchasing an additional 21 shares during the period. First Financial Corp IN lifted its holdings in Humana by 7.2% during the 4th quarter. First Financial Corp IN now owns 343 shares of the insurance provider's stock valued at $157,000 after buying an additional 23 shares in the last quarter. First Trust Direct Indexing L.P. boosted its position in Humana by 0.8% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 2,926 shares of the insurance provider's stock valued at $1,424,000 after buying an additional 24 shares during the period. Nvwm LLC grew its stake in Humana by 41.0% in the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider's stock worth $42,000 after acquiring an additional 25 shares in the last quarter. Finally, Community Bank & Trust Waco Texas increased its position in shares of Humana by 3.7% during the third quarter. Community Bank & Trust Waco Texas now owns 841 shares of the insurance provider's stock worth $408,000 after acquiring an additional 30 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

NYSE HUM traded down $0.49 on Wednesday, reaching $324.14. 1,278,149 shares of the company's stock traded hands, compared to its average volume of 1,967,296. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $541.21. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The firm has a market cap of $39.06 billion, a price-to-earnings ratio of 20.18, a P/E/G ratio of 1.86 and a beta of 0.49. The stock has a 50 day moving average price of $323.08 and a 200-day moving average price of $385.94.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts' consensus estimates of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company's revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.38 earnings per share. Equities research analysts predict that Humana Inc. will post 16.18 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date of this dividend is Friday, June 28th. Humana's dividend payout ratio (DPR) is presently 22.04%.

Insider Activity at Humana

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the purchase, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Jefferies Financial Group dropped their price objective on Humana from $411.00 to $381.00 and set a "buy" rating on the stock in a research note on Monday, April 22nd. StockNews.com lowered shares of Humana from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 26th. Argus downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Wednesday, March 13th. The Goldman Sachs Group dropped their price objective on shares of Humana from $450.00 to $385.00 and set a "buy" rating on the stock in a research note on Wednesday, April 3rd. Finally, Barclays reduced their price objective on shares of Humana from $356.00 to $310.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Humana currently has an average rating of "Hold" and an average target price of $424.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.